A case of Hallervorden-Spatz disease presenting as catatonic schizophrenia
A 28-year-old married man presented to the psychiatry outpatient department with complaints of staring spells, maintaining odd postures for long time, decreased sleep, not eating or drinking, tremulousness in the body, stiffness of hands and legs and deviation of the angle of mouth. All these complaints were present since 10-15 days. His illness started 4 years back when, without any precipitating stressors, he developed gradual onset suspiciousness on neighbors, irrelevant talk, muttering and gesticulating to self with occasional history of aggressiveness. Although he was taking treatment from some psychiatrist, details of this treatment were not known and moreover he was not maintained on regular treatment. He was brought to the psychiatry outpatient department for acute deterioration in his symptoms.\nThere was no history of affective features, substance use, any other psychiatric illness and other medical or surgical illness. He was born full-term and had attained childhood milestones normally. He had poor scholastic performance from 5th grade, after which he left studies. Even after his school he did not seem very keen on doing some work. He would frequently change his jobs for no apparent reasons. He was temperamentally quiet, introvert and shy.\nHis general examination was within normal limits but nervous system examination revealed rigidity and diminished reflexes in all four limbs. Systemic examination did not reveal anything substantial.\nIn view of his past psychiatric history of four years and increased presenting complaints since 10-15 days, he was provisionally given a diagnosis of catatonic schizophrenia with neuroleptic induced extrapyramidal reaction (EPR). He was admitted to the psychiatry inpatient unit.\nIn the psychiatric ward, he was started on clozapine (25 mg HS), trihexyphenidyl (6 mg) and diazepam (5 mg) along with monitoring of vitals and adequate hydration. Since the patient was suspected to have drug induced EPR and clinically he had catatonia, we wanted to make sure that he does not develop drug induced EPR that may have complicated the picture, hence clozapine was the best choice in this case. His routine blood investigations (such as complete blood count, renal and liver function tests) and fundus examination were within normal limits. Brain CT scan revealed bilateral basal ganglia calcification [].\nAs there was no improvement in his catatonic features, he was started on electroconvulsive therapy (ECT) on fourth day of his admission (ECT being the best treatment for catatonia). However, even after 3 ECTs there was no improvement in his rigidity; instead he started remaining confused. Hence all his medications and ECTs were stopped. His serum electrolytes were within normal limits but serum creatine phosphokinase (CPK) levels were elevated to 3493 U/L (Normal limit: 35-232 U/L). A neuromedicine reference was taken and he was subsequently diagnosed as neuroleptic malignant syndrome (NMS) and started on bromocriptine 2.5 mg thrice daily.\nAfter 3 days of bromocriptine, there was improvement in his condition; his confusion and rigidity had decreased considerably. By day 15, his serum CPK levels had decreased (220 U/L) after which he was restarted on clozapine 12.5 mg for psychosis (clozapine being the least D2 antagonist is the safest choice in such cases). However, within the first day of clozapine re-dosing, his confusion increased and condition deteriorated. Hence clozapine was stopped. In view of his increasing psychosis, ECTs were restarted by day 17th. His repeat serum CPK levels on days 18 and 29 showed an increasing level (386 U/L and 563 U/L). His rigidity had also increased by 7th ECT. Valproate was added as he developed affective features in the form of excessive cheerfulness and jocularity, singing songs, and over-familiarity in the ward. Along with this, baclofen and injection magnesium sulfate (4 gm once a day for 3 days) were also added. However, patient's condition further deteriorated and he developed urinary and fecal incontinence. Again both ECTs and valproate were stopped for nearly 15 days during which he was given bromocriptine (2.5 mg thrice daily; dopamine agonist), baclofen (30 mg at bedtime; muscle relaxant) and diazepam (5 mg at bedtime).\nDespite these medications, his early morning rigidity, urinary and fecal incontinence did not improve. He was again referred for a neuromedicine opinion in view of persistently rising serum CPK levels and rigidity. The patient was given a differential diagnosis of Hallervorden-Spatz Disease, Wilson's disease, neuroleptic malignant syndrome, Huntington's disease and hypoparathyroidism. Wilson's disease was ruled out by serum ceruloplasmin level (49.23 mg/dl), serum copper (94 μg/dl) and 24 hrs urine copper level (32 μg/24 hrs) and ophthalmic examination for KF ring (which was negative). Huntington's disease was ruled out by genetic testing for CAG repeats. Hypoparathyroidism was ruled out when serum calcium (9.1 mg/dl), serum phosphate (3.6 mg/dl), serum magnesium (2.4 mg/dl), alkaline phosphatase (98 U/L) and PTH (42 pg/ml) levels were reported within normal limits. MRI brain (T2W images) revealed bilaterally symmetric hyperintense signal changes in globus pallidus with surrounding hypointensity [] suggestive of tiger-eye appearance found in Hallervorden-Spatz disease. Genetic testing could not be done due to non-availability of the test in our set up. Finally he was given a diagnosis of Hallervorden-Spatz disease by day 49 of admission to psychiatric ward. He was maintained on baclofen 10 mg four times a day and bromocriptine 5 mg thrice a day. Patient showed a gradual improvement, with his psychosis, rigidity and serum CPK level (50 U/L) decreasing. He was discharged at request by 50th day.\nAfter a fortnightly follow-up, patient was much improved in so far as his psychotic or catatonic symptoms were concerned. He did not have any rigidity, dystonia or neurodeficits. His last CPK levels were within normal limits (67 IU). However the patient was subsequently lost to follow-up after a month.